Trials / Recruiting
RecruitingNCT07406633
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Kumquat Biosciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.
Conditions
- GIST - Gastrointestinal Stromal Tumor
- GIST
- GIST Metastatic Cancer
- Gastro Intestinal Stromal Tumour
- Gastrointestinal Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KQB198 | Oral KQB198 |
| DRUG | Imatinib (Gleevec) | Oral Imatinib |
Timeline
- Start date
- 2026-05-01
- Primary completion
- 2027-10-01
- Completion
- 2028-10-01
- First posted
- 2026-02-12
- Last updated
- 2026-04-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07406633. Inclusion in this directory is not an endorsement.